

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE		ING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/053,302	10/053,302 01/17/2002		Kyung Jin Kim	A-67640-2/RFT/NBC	6859
23552	7590	08/03/2005		EXAMINER	
MERCHAN P.O. BOX 29		JLD PC	NOLAN, PATRICK J		
MINNEAPO		55402-0903		ART UNIT	PAPER NUMBER
•				1644	·

DATE MAILED: 08/03/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)						
		10/053,302	KIM ET AL.						
	Office Action Summary	Examiner	Art Unit						
		Patrick J. Nolan	1644						
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply									
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).									
Status									
1)⊠	Responsive to communication(s) filed o	n <i>31 May 2005</i> .		·					
,	•	This action is non-final.							
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the ments is								
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.								
Disposition of Claims									
	4) Claim(s) <u>1-3,5-11 and 14-23</u> is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration.								
	5) Claim(s) is/are allowed.								
· · · · · · · · · · · · · · · · · · ·	☑ Claim(s) <u>1-3,5-11 and 14-23</u> is/are rejected.								
7)									
8)□	_								
Application Papers									
9) The specification is objected to by the Examiner.									
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.									
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).									
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.									
Priority under 35 U.S.C. § 119									
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 									
Attachmen	t(s)								
	e of References Cited (PTO-892)		ew Summary (PTO-413) No(s)/Mail Date						
3) 🛛 Inforr	e of Draftsperson's Patent Drawing Review (PTO-s nation Disclosure Statement(s) (PTO-1449 or PTO r No(s)/Mail Date <u>5-31-05</u> .		of Informal Patent Application (PT	O-152)					

Office Action Summary

Application/Control Number: 10/053,302 Page 2

Art Unit: 1644

1. Claims 1-3, 5-11, 14-20 and newly added claims 21-23 are pending.

2. Claims 1-3, 5-11, 14 and newly added claims 21-23 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-5, 13-15 and 20-22 of copending Application No. 08/943,771. Although the conflicting claims are not identical, they are not patentably distinct from each other because the '771 pending claims are species claims to the instantly pending claims in the current application.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Applicant has stated a 08/943,771 will go abandoned. As of 8-2-05 it is still pending The rejection is maintained.

3. A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer <u>cannot</u> overcome a double patenting rejection based upon 35 U.S.C. 101.

Claims 19-20 stand provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1 and 5 of copending Application No. 08/943,771. This is a provisional double patenting rejection since the conflicting claims have not in fact been patented.

Both sets of claims are drawn to the same exact deposited monoclonal antibody, ID3 or an antibody that competes with said antibody.

Applicant has stated a 08/943,771 will go abandoned. As of 8-2-05 it is still pending.

Application/Control Number: 10/053,302

Art Unit: 1644

The rejection is maintained.

4. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

5. Claims 1-3, 5-11, 14-20 and newly added claims 21-23 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention, for reasons of record in the Office Action mailed 2-28-05.

Applicant argues they have support in the originally filed claims.

A careful review of the specifications and claims of 60/061,185 and 09/166,298 finds no support for the term "or progeny thereof".

Furthermore, in claims 21 and 22, while the specification clearly supports the deposited monoclonal antibodies to be able to block the activity of IFN-α8, 5, 2 and not IFN-β, it does support an antibody that competes for binding to IFNAR2 AND has those properties.

6. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event,

Application/Control Number: 10/053,302 Page 4

Art Unit: 1644

however, will the statutory period for reply expire later than SIX MONTHS from the mailing

date of this final action.

7. The fax number for the organization where this application or proceeding is assigned is

571-273-8300.

8. Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private

PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Patrick Nolan whose telephone number is 571-272-0847.

If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Christina

Chan, can be reached at 571-272-0841.

Patrick J. Nolan, Ph.D.

Primary Examiner, Group 1640

August 2, 2005